New data on Medtronic's Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week. A pair of analyses released during the the European Society of Cardiology Congress in Amsterdam this week showed positive results for the hypertension treatment system.
Medtronic Announces Formation of Hospital Solutions Business Aimed at Driving Efficiencies and Cost SavingsSeptember 2, 2013 12:06 pm | by The Associated Press | News | Comments
Medtronic, Inc. (NYSE: MDT) today announced the formation of Medtronic Hospital Solutions, a new business focused on developing novel partnerships with hospitals to provide services directly related to hospital operational efficiency. The new business will focus initially on offering services in Europe...
When Medtronic announced that it paid $200 million in cash for chronic disease management firm Cardiocom the medical device giant said the acquisition was indicative of a broader vision for the company's future, but Wall Street analysts are warning that it may also suggest "challenging times ahead" for the device industry.
Medical device giant Medtronic is handing its Pioneer Plus re-entry catheter product line over to Volcano for an undisclosed amount, the companies announced this week. The deal, which Volcano hopes will help it expand its reach in peripheral indications, is expected to close this month and is structured as an "asset purchase."
Another patient injury lawsuit is set to proceed against Medtronic and it's problematic Infuse bone-growth protein after an Arizona district judge ruled that federal preemption doesn't apply in a case accusing the company of off-label marketing, a relatively new tactic that is proving somewhat successful for patients waging battles against medical device makers.
Volcano Corporation Announces Execution Of Agreement To Purchase Pioneer PlusT Re-Entry Catheter Product Line From MedtronicAugust 26, 2013 4:05 pm | by The Associated Press | News | Comments
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today it has signed an agreement to acquire the Pioneer PlusT diagnostic ultrasound ...
Starting today, medical device giant Medtronic is banned from selling its CoreValve and CoreValve Evolut transcatheter aortic valve implantation systems in Germany, thanks to a court ruling in favor of rival device maker Edwards Lifesciences.
Kent L. Klaudt, lawyer at the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that U.S. District Court Judge G. Murray Snow of the District of Arizona denied in large part Medtronic’s motion to dismiss a personal injury lawsuit brought by Dr. Cristina Ramirez against the company on grounds that the claims are preempted by Federal law.
Investors pushed shares of Medtronic down this morning after the world's largest pure-play medical device company reported mixed results for its fiscal 1st quarter. Fridley, Minn.-based Medtronic posted profits of $953 million, or 93¢ per share, on sales of $4.08 billion for the 3 months ended July 26.
Premier Healthcare Alliance awarded several new contracts for drug-eluting stents, traditional stents and other intervention products to 8 heavy hitters in the cardiology space. Abbott, Boston Scientific, and Medtronic all landed supplier deals for drug-eluting and traditional stents.
Medtronic Inc. said Monday that it closed its $200 million acquisition of Cardiocom, which develops and provides services that help manage chronic diseases. The Minneapolis-based medical device maker said it doesn't expect the deal to affect its fiscal year 2014 profit.
Medtronic, Inc. has announced the first implant of a novel deep brain stimulation (DBS) system that, for the first time, enables the sensing and recording of select brain activity while simultaneously providing targeted DBS therapy. This initiates research on how the brain responds to the therapy...
A new brain implant that can record neural activity while it simultaneously delivers electric current has been implanted into a patient for the first time. The new device from Medtronic, a Minneapolis-based medical device company, can also adjust its electrical output in response to the changing conditions of the brain.
The battle over Medtronic's Infuse bone-growth protein continues to be a roller-coaster, with judges in 2 states issuing seemingly conflicting rulings about the validity of patient injury lawsuits against the Minnesota medical device giant and its troubled Infuse bone-growth protein.
Medtronic, one of the world’s largest medical technology companies, has entered into an innovative partnership with The Johns Hopkins University, agreeing to provide $200,000 a year for up to three years and skilled mentoring to help biomedical engineering students design new healthcare solutions for underserved patients in developing countries.
Edwards Lifesciences wants a federal judge to rule that a pair of patents owned by arch-rival Medtronic are invalid because they aren't specific enough. The patents cover nerve stimulation technology. Edwards and Medtronic have spent considerable time in courts around the world, each arguing that the other's transcatheter aortic valve implant infringes various patents.
The FDA put its highest-risk label, Class I, on a recall of Medtronic's (NYSE:MDT) Paradigm insulin infusion pumps, which the medtech giant had warned about earlier this year. Medtronic Canada said last month that it received 2 reports on its Paradigm and Polyfin infusion devices, concerning the over- and under-delivery of insulin therapy.
Medtronic (NYSE:MDT) prevailed in an antitrust lawsuit filed over a bone mill made by Lenox MacLaren Surgical, with a federal judge ruling that Lenox misrepresented the size of the bone mill market and failed to adequately market its own device.
Some 55 U.S. hospitals agreed to pay a total of $34 million to settle U.S. Justice Dept. charges that they overcharged Medicare for Medtronic's (NYSE:MDT)'s kyphoplasty spine procedure, acquired in the $3.9 billion buyout of Kyphon in 2007, the Justice Dept. said today.
Minnesota medical device giant Medtronic (NYSE:MDT) confirmed today that it recalled certain of its already-troubled Infuse spinal fusion surgery kits after learning of possible contamination in sponges manufactured by Integra Lifesciences.
In June 2013, Medtronic, Inc. (NYSE: MDT) initiated four medical device notifications to customers worldwide about the SynchroMed® Implantable Infusion System. These notifications provide clinicians with information to help identify and manage issues that impact the safe and reliable delivery of therapy using the SynchroMed Implantable Infusion System.
In November 2012 and February 2013, Andrew Johnson underwent a surgical procedure, Deep Brain Stimulation surgery, to help control his motor symptoms. This video represents his experience of how DBS has helped him. He is using a device from Medtronic.
Doctors are reporting a major step toward an "artificial pancreas," a device that would constantly monitor blood sugar in people with diabetes and automatically supply insulin as needed. A key component of such a system—an insulin pump programmed to shut down if blood-sugar dips too low while people are sleeping—worked as intended in a three-month study of 247 patients.
ALRT's Internet-Based Glucose Monitoring Platform Compares Favorably with Medtronic's Continuous Glucose Monitoring SystemJune 24, 2013 8:18 am | by The Associated Press | News | Comments
This weekend, ALR Technologies announced at the American Diabetes Association meeting in Chicago that the A1c reduction in insulin-requiring patients with type 2 diabetes mellitus who managed their blood glucose using ALRT's Internet-Based Glucose Monitoring (IBGMS) platform, "Health-e-Connect", demonstrated comparable results to patients using Medtronic's "Guardian REAL-Time Continuous Glucose Monitoring System" (RT-CGM).
Shares of Medtronic slipped Tuesday, a day after the medical device maker announced findings from independent reviews of studies of its Infuse bone graft. The Minneapolis company said the reviews, conducted through Yale University, concluded that clinical success rates with its Infuse product were equivalent to more traditional bone graft procedures in which bone is taken from the hip.